Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables - Net (2018 - 2025)

Historic Receivables - Net for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to $16.8 million.

  • Zevra Therapeutics' Receivables - Net rose 11618.74% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 11618.74%. This contributed to the annual value of $10.5 million for FY2024, which is 3952.35% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Receivables - Net stood at $16.8 million, which was up 11618.74% from $18.3 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Receivables - Net registered a high of $18.3 million during Q2 2025, and its lowest value of $1.5 million during Q4 2021.
  • Its 5-year average for Receivables - Net is $8.9 million, with a median of $8.3 million in 2024.
  • The largest annual percentage gain for Zevra Therapeutics' Receivables - Net in the last 5 years was 44312.83% (2022), contrasted with its biggest fall of 7064.03% (2022).
  • Over the past 5 years, Zevra Therapeutics' Receivables - Net (Quarter) stood at $1.5 million in 2021, then soared by 443.13% to $8.3 million in 2022, then soared by 109.39% to $17.4 million in 2023, then crashed by 39.52% to $10.5 million in 2024, then surged by 60.25% to $16.8 million in 2025.
  • Its Receivables - Net stands at $16.8 million for Q3 2025, versus $18.3 million for Q2 2025 and $12.6 million for Q1 2025.